35 / 38
Where can we use it? Potential algorithm
Molina A, et al. Eur J Cancer 2018
Good risk
Intermediate or Poor
risk
First Line
Options
Sunitinib
Pazopanib
Nivolumab + Ipilimumab
Cabozantinib
Second Line
Post-TKI
Nivolumab
Cabozantinib
Axitinib
Post-IO
Any TKi